Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 755 results for end of life care

  1. The Moth TalkCPR Art in Medicine Project

    journey we took to consider whether graphic design in medical palliative care settings could be a powerful and effective way of...

  2. Pancreatic cancer (QS177)

    This quality standard covers diagnosis of pancreatic cancer and management of pancreatic ductal adenocarcinoma in adults aged over 18. This quality standard describes high-quality care in priority areas for improvement. It does not cover national initiatives, such as cancer screening or audit.

  3. Cirrhosis in over 16s: assessment and management (NG50)

    This guideline covers assessing and managing suspected or confirmed cirrhosis in people who are 16 years or older. It aims to improve how cirrhosis is identified and diagnosed, and gives advice on the monitoring, prevention and early management of complications.

  4. Mental wellbeing of older people in care homes (QS50)

    This quality standard covers the mental wellbeing of older people (aged 65 and over) receiving care in care homes (including residential and nursing accommodation, day care and respite care). It focuses on support for people to improve their mental wellbeing so that they can stay as well and independent as possible. It describes high-quality care in priority areas for improvement.

  5. Spinal metastases and metastatic spinal cord compression (NG234)

    This guideline covers recognition, referral, investigation and management of spinal metastases and metastatic spinal cord compression (MSCC). It is also relevant for direct malignant infiltration of the spine and associated cord compression. It aims to improve early diagnosis and treatment to prevent neurological injury and improve prognosis.

  6. Brain tumours (primary) and brain metastases in over 16s (NG99)

    This guideline covers diagnosing, monitoring and managing any type of primary brain tumour or brain metastases in people aged 16 or over. It aims to improve diagnosis and care, including standardising the care people have, how information and support are provided, and palliative care.

  7. Does early review and referral to specialist palliative care services improve outcomes for adults with COVID-19 thought to be approaching the end of their life?

    to specialist palliative care services improve outcomes for adults with COVID-19 thought to be approaching the end of their...

  8. Developing and implementing guidance for staff delegating clinical tasks to informal carers and relatives during the COVID-19 pandemic

    LiveWell Southwest, a social enterprise company delivering integrated care to patients in both urban and rural regions of South West...

  9. Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer (TA638)

    Evidence-based recommendations on atezolizumab (Tecentriq) for untreated extensive-stage small-cell lung cancer in adults.

  10. Moving between hospital and home, including care homes

    NICE quick guide - moving between hospital and home, including care homes

  11. Managing COVID symptoms (including at the end of life) in a prison setting

    ensured that the healthcare delivery within the prisons reflected the same care escalation plan as other healthcare colleagues across...

  12. Depression in children and young people: identification and management (NG134)

    This guideline covers identifying and managing depression in children and young people aged 5 to 18 years. Based on the stepped-care model, it aims to improve recognition and assessment and promote effective treatments for mild and moderate to severe depression.

  13. Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy (TA713)

    Evidence-based recommendations on nivolumab (Opdivo) for advanced non-squamous non-small-cell lung cancer in adults after chemotherapy.

  14. Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease (TA449)

    Evidence-based recommendations on everolimus (Afinitor) and sunitinib (Sutent) for treating neuroendocrine tumours in adults.

  15. Reviewing the impact of our guidance

    Our impact reports look at how the health and care system uses NICE's recommendations to improve people's health and care.